Bypassing defective HPDL-mediated CoQ10 synthesis using 4-hydroxymandelate and 4-hydroxybenzoate precursors to restore endogenous brain CoQ10 production, addressing blood-brain barrier limitations of direct supplementation while mechanistically reversing mitochondrial dysfunction and neurodegeneration in acquired CoQ10 deficiencies through targeted headgroup intermediate delivery.